About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT05496348

Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will assess how effective upa...

Lead sponsor: AbbVie•94 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Medical Information Germany

CONTACT

49 611 1720 1520 medinfo.germany@abbvie.com

Sponsors

Lead Sponsor

AbbVie

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Participants with an endoscopically confirmed diagnosis of active moderate to severe Ulcerative colitis (UC).
•Participants initiating Upadacitinib (UPA) at the investigator's discretion as part of their routine clinical care; the decision to administer UPA must be made prior to and independent of documentation for the study and according to the approved local label.
•Participants able to understand and communicate with the investigator and comply with the requirements of the study.
•Participants willing to continue with study documentation after cessation of UPA.

Exclusion Criteria

•Participants with any contraindication to Upadacitinib (UPA).
•Participants previously exposed to a Janus kinase (JAK) inhibitor.

Related studies

RECRUITINGPhase 3

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more

RECRUITINGPhase 4

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）

NCT07550673 · Acute Severe Ulcerative Colitis

Association Between LRG and Histologic Remission in Ulcerative Colitis

NCT06372613 · Ulcerative Colitis in Histologic Remission

RECRUITINGPhase 1/2

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

NCT07374471 · Ulcerative Colitis (UC)

RECRUITINGPhase 1/2

FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach

NCT06071312 · Clostridium Difficile, Ulcerative Colitis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 3, 2026Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment400

Start dateOct 2022

Last updatedFeb 3, 2026

Condition

Ulcerative Colitis

Locations shown

Kepler Universitaetsklinikum GmbH /ID# 251868

Linz, Upper Austria

Krankenhaus der Barmherzigen Brueder Wien /ID# 251867

Vienna, Vienna

Krankenhaus der Barmherzigen Brueder Salzburg /ID# 251869

Salzburg

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 3, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions